

# WUENIC Talking Points: State of Palestine

Revision Year: 2025

## Contents

|                                                                               |   |
|-------------------------------------------------------------------------------|---|
| Overview . . . . .                                                            | 2 |
| DTP1: Reaching zero-dose children . . . . .                                   | 3 |
| DTP3: A marker of routine immunization service delivery to children . . . . . | 4 |
| MCV: Canary in the coal mine . . . . .                                        | 5 |
| HPV . . . . .                                                                 | 6 |
| Regional Comparison . . . . .                                                 | 7 |
| Additional Vaccines . . . . .                                                 | 8 |
| Appendix . . . . .                                                            | 9 |

### State of Palestine in the 'Asia' region



## Overview

- A total of 13 childhood vaccines are tracked for the State of Palestine; of these, 12 reached the 90% coverage target or higher in 2025.
- Coverage of the first dose of diphtheria-tetanus-pertussis-containing vaccine (DTP1) was the same in 2025 as it was in 2024 (99%), coverage of the third dose of DTP-containing vaccine (DTP3) was the same in 2025 as it was in 2024 (99%), and coverage of the first dose of the measles-containing vaccine (MCV1) declined from 99% in 2024 to 98% in 2025.
- In 2025, the number of zero-dose children for DTP in the State of Palestine (1,000) was approximately 35% higher than the annual number proposed to achieve the IA2030 target of halving zero-dose children for DTP by 2030 (1,000), based on a linear trajectory of decline.


**Vaccine coverage (%), State of Palestine, 2000–2025**

|       | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|-------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| BCG   | 92   | 97   | 96   | 99   | 98   | 99   | 99   | 99   | 99   | 99   | 98   | 98   | 98   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 87   | 99   | 98   |
| HepBB | 95   | 94   | 93   | 95   | 97   | 98   | 99   | 99   | 95   | 95   | 96   | 96   | 97   | 97   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 95   | 84   | 98   | 98   |
| DTP1  | 95   | 97   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 98   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 88   | 99   | 99   |
| DTP3  | 93   | 97   | 97   | 98   | 96   | 96   | 96   | 99   | 96   | 97   | 99   | 99   | 97   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 98   | 95   | 98   | 88   | 99   | 99   |
| Hib3  |      |      |      |      |      |      |      | 96   | 96   | 97   | 99   | 99   | 97   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 98   | 95   | 98   | 88   | 99   | 99   |
| HepB3 | 95   | 92   | 91   | 97   | 96   | 99   | 97   | 98   | 96   | 97   | 98   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 98   | 95   | 99   | 91   | 99   | 99   |
| PCVC  |      |      |      |      |      |      |      |      |      |      |      |      | 25   | 97   | 99   | 99   | 99   | 99   | 96   | 99   | 98   | 95   | 99   | 87   | 99   | 99   |
| RotaC |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      | 99   | 99   | 99   | 99   | 87   | 93   | 83   | 97   | 83   |
| IPV1  |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 86   | 99   | 98   |
| IPVC  |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      | 97   | 99   | 86   | 99   | 98   |
| MCV1  | 93   | 98   | 94   | 99   | 96   | 98   | 99   | 98   | 96   | 97   | 98   | 99   | 98   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 98   | 97   | 89   | 99   | 98   |
| RCV1  | 95   | 94   | 93   | 94   | 94   | 97   | 92   | 87   | 99   | 97   | 94   | 99   | 98   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 98   | 97   | 89   | 99   | 98   |
| MCV2  | 95   | 94   | 93   | 94   | 94   | 97   | 92   | 87   | 99   | 97   | 94   | 95   | 97   | 98   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 93   | 89   | 99   | 99   |



Source: WHO/UNICEF estimates of national immunization coverage, 2025 revision.

**Estimated number of zero-dose children, 2000–2025 and target by 2030, the State of Palestine**




Source: WHO/UNICEF estimates of national immunization coverage, 2025 revision.  
 Note: The Immunization Agenda 2030 (IA2030) calls on all countries to reduce the number of zero-dose children in 2019 in half by 2030.  
 Dark blue bars are the estimated number of zero-dose children in 2000–2025.  
 Light blue bar is the target number of zero-dose children by 2030.  
 The line and points show the yearly progress and trajectory to meet the target by 2030, based on a linear decline.

## DTP1: Reaching zero-dose children

- Coverage of DTP1 stood at 99% in 2025. This is the same as in 2019 (99%) and the same as in 2024 (99%).
- The percentage of zero-dose children was 35 percentage points higher than the IA2030 target in 2025. There were approximately 1,000 zero-dose children in 2025, fewer than the 1,000 in 2019 but more than the 1,000 in 2024.
- Coverage of DTP1 in the State of Palestine (99%) was higher than the Middle East and North Africa regional average of 89% in 2025.
- DTP1-to-DTP3 dropout in 2025 was 0%, the same as in 2019. Low DTP dropout rates imply good ability to provide a complete vaccine series early in life.


**DTP1 coverage and zero-dose children over time, State of Palestine, 2000–2025**



Dotted line shows the IA2030 target of 90% coverage  
Source: WHO/UNICEF estimates of national immunization coverage, 2025 revision.

## DTP3: A marker of routine immunization service delivery to children


- Coverage of DTP3 stood at 99% in 2025. This is the same as in 2019 (99%) and the same as in 2024 (99%).
- The number of children vaccinated with DTP3 decreased from 144,000 in 2019 to 141,000 in 2025.
- In 2025, there were 1,000 children un- or under-vaccinated in the State of Palestine.
- In 2025, 0% of children who received DTP1 did not receive DTP3. This 0% dropout rate was the same as in 2019 (0%) and the same as the 2024 dropout rate (0%).
- Coverage of DTP3 in the State of Palestine (99%) was higher than the Middle East and North Africa regional average of 83% in 2025.



Dotted line shows the IA2030 target of 90% coverage  
 Source: WHO/UNICEF estimates of national immunization coverage, 2025 revision.

## MCV: Canary in the coal mine

- Coverage of MCV1 stood at 98% in 2025. This is lower than in 2019 (99%) and lower than in 2024 (99%).
- Coverage of the second dose of the measles-containing vaccine (MCV2) remained relatively stable, within 1 percentage point of the 2019 level. This leaves 3,000 children without any protection against measles and another -1,000 with only partial protection.
- In 2025, 1% of children who received DTP1 did not receive MCV1. This 1% dropout rate was 1 percentage points higher than in 2019 (0%) and 1 percentage points higher than the 2024 dropout rate (0%).
- The State of Palestine has achieved MCV1 coverage above 80% over all of the last 3 years.
- Coverage of MCV1 in the State of Palestine (98%) was higher than the Middle East and North Africa regional average of 84% in 2025.



Dotted line shows the IA2030 target of 90% coverage  
 Source: WHO/UNICEF estimates of national immunization coverage, 2025 revision.

## HPV


- State of Palestine had not introduced human papillomavirus vaccination (HPV) as of 2025.

## Regional Comparison

The chart below shows how the State of Palestine compares to other countries in the Middle East and North Africa region on DTP1, DTP3, MCV1 coverage in 2025. The dashed line represents the regional average for each vaccine.

### Coverage comparison: State of Palestine vs. MENA peers, 2025

Dashed line = regional average



Source: WHO/UNICEF estimates of national immunization coverage, 2025 revision.

## Additional Vaccines

- Coverage of BCG stood at 98% in 2025. This is lower than in 2019 (99%) and lower than in 2024 (99%).
- Coverage of HepB3 stood at 99% in 2025. This is the same as in 2019 (99%) and the same as in 2024 (99%).
- Coverage of Hib3 stood at 99% in 2025. This is the same as in 2019 (99%) and the same as in 2024 (99%).
- Coverage of IPV1 stood at 98% in 2025. This is lower than in 2019 (99%) and lower than in 2024 (99%).
- Coverage of PCVC stood at 99% in 2025. This is the same as in 2019 (99%) and the same as in 2024 (99%).
- Coverage of RotaC stood at 83% in 2025. This is lower than in 2019 (99%) and lower than in 2024 (97%).

**Additional vaccine coverage (%), State of Palestine, 2000–2025**

|       | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|-------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| BCG   | 92   | 97   | 96   | 99   | 98   | 99   | 99   | 99   | 99   | 99   | 98   | 98   | 98   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 87   | 99   | 98   |
| HepB3 | 95   | 92   | 91   | 97   | 96   | 99   | 97   | 98   | 96   | 97   | 98   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 98   | 95   | 99   | 99   | 91   | 99   | 99   |
| Hib3  |      |      |      |      |      |      |      | 96   | 96   | 97   | 99   | 99   | 97   | 99   | 99   | 99   | 99   | 99   | 99   | 98   | 95   | 98   | 98   | 88   | 99   | 99   |
| IPV1  |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 99   | 86   | 99   | 98   |
| PCVC  |      |      |      |      |      |      |      |      |      |      |      |      | 25   | 97   | 99   | 99   | 99   | 99   | 96   | 99   | 98   | 95   | 99   | 87   | 99   | 99   |
| RotaC |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      | 99   | 99   | 99   | 99   | 87   | 93   | 83   | 97   | 83   |



Source: WHO/UNICEF estimates of national immunization coverage, 2025 revision.



## Appendix

### WHO/UNICEF Estimates of National Immunization Coverage (WUENIC)

Each year, WHO and UNICEF review national immunization data from Member States, including administrative and official coverage, survey estimates and contextual information, and use rules-based data triangulation approach to assess coverage. Estimates are produced independently, without borrowing data from other countries, and are not based on ad hoc adjustments. In some cases, they rely on a single source, typically nationally reported coverage. When data for a specific country-vaccine-year are unavailable, values from adjacent years are interpolated or extrapolated, and conflicting sources are assessed to determine the most reliable estimate, considering potential biases and expert opinion.

Methods:

- [Burton et al. 2009. WHO and UNICEF estimates of national infant immunization coverage: methods and processes](#)
- [Burton et al. 2012. A formal representation of the WHO and UNICEF estimates of national immunization coverage: a computational logic approach](#)
- [Brown et al. 2013. An introduction to the grade of confidence used to characterize uncertainty around the WHO and UNICEF estimates of national immunization coverage](#)

These talking points present the latest WUENIC estimates (published 15 July 2026).

### Definitions of immunization terms:

- Bacillus Calmette-Guerin (BCG): vaccine against tuberculosis
- Hepatitis B birth dose, given within 24 hours after birth (HepBB)
- Diphtheria, tetanus, and pertussis vaccine, first dose (DTP1) and third dose (DTP3)
- Hepatitis B vaccine, third dose (HepB3)
- Haemophilus influenzae type B vaccine, third dose (Hib3)
- Inactivated polio vaccine, first dose (IPV1) and last dose (IPVC)
- Measles containing vaccine, first dose (MCV1) and second dose (MCV2)
- Rotavirus vaccine, last dose (RotaC)
- Pneumococcal vaccine, last dose (PCV)
- Yellow Fever vaccine (YFV)
- Meningococcal A vaccine (MengA)
- Human Papillomavirus vaccine, first dose (HPV1) and last dose (HPVc)

**Additional resources:** <https://data.unicef.org/resources/immunization/>